Insiders who reported open-market trades in the last 12 months at the companies Richard Scott Struthers files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Jeff E. Knight - $3.79M in CRNX purchases and sales in the last 12 months
Dana Pizzuti - $438K in CRNX purchases and sales in the last 12 months
Stephen F. Betz - $397K in CRNX purchases and sales in the last 12 months
Stephanie Okey - $365K in CRNX purchases and sales in the last 12 months
Richard Scott Struthers is a corporate insider, tracked as President & CEO, Director of Crinetics Pharmaceuticals, Inc. (CRNX). InsiderAlpha holds 7 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Richard Scott Struthers submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Richard Scott Struthers been buying or selling stock?
Recorded transactions: 0 open-market purchases and 4 open-market sales ($1.58M) across all tracked filings.
Richard Scott Struthers is President & CEO, Director of Crinetics Pharmaceuticals, Inc. (CRNX). 7 SEC Form 4 filings on record going back to 2024, most recently on 1 September 2026. Lifetime open-market sales: $1.58M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Richard Scott Struthers.
InsiderAlpha's records for Richard Scott Struthers go back to 2024: 7 primary Form 4 filings, an average of 2.3 per year. 3 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
